GlobeNewswire Clinical StudiesOriginal article
Intelligent Bio Solutions Announces Completion of Method Comparison Study for the Intelligent Fingerprinting Drug Screening System
RegulatoryIntelligent Fingerprinting Drug Screening SystemPositive
AI Analysis
Summary
Intelligent Bio Solutions completed clinical data collection for its Intelligent Fingerprinting Drug Screening System 510(k) FDA submission, which remains on track for the second half of 2026.
Clinical Trial Data
Outcome Details
Clinical data collection complete for FDA 510(k) submission
Importance:6/10
Sentiment:
0.60
510(k)FDA submissionclinical studydrug screeningregulatory milestone
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on August 11, 2026 12:30 PM